Core Insights - Hansen Pharmaceutical reported third-quarter revenue of 232 million yuan, representing a year-on-year increase of 8.62% [1] - The net profit for the third quarter was 13.9868 million yuan, showing a year-on-year decline of 53.78% [1] - For the first three quarters, the total revenue reached 741 million yuan, reflecting a year-on-year growth of 6.75% [1] - The net profit for the first three quarters was 82.5252 million yuan, which is a year-on-year decrease of 36.88% [1]

证券代码：002412 证券简称：汉森制药 公告编号：2025-025 湖南汉森制药股份有限公司 关于召开 2025 年第一次临时股东大会的通知 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记 载、误导性陈述或者重大遗漏。 一、召开会议的基本情况 1、股东大会届次：2025 年第一次临时股东大会 2、股东大会的召集人：董事会 5、会议的召开方式：现场表决与网络投票相结合。 6、会议的股权登记日：2025 年 11 月 10 日 7、出席对象 （1）截止 2025 年 11 月 10 日下午交易结束后在中国证券登记结算有限责任公 司深圳分公司登记在册的公司全体普通股股东，均有权出席本次股东大会及参加表 决；因故不能亲自出席会议的股东可书面授权代理人出席和参加表决（该股东代理 人可不必是公司的股东）。 （2）公司董事、监事和高级管理人员。 （3）公司聘请的律师。 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所股 票上市规则》《深圳证券交易所上市公司自律监管指引第 1 号——主板上市公司规范 运作》等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-022 湖南汉森制药股份有限公司 第六届监事会第九次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或者重大遗漏。 一、监事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届监事会第九次会议 于 2025 年 10 月 24 日在公司一楼会议室召开，本次会议由公司监事会主席刘赛 程女士召集主持，会议通知于 2025 年 10 月 13 日以专人递送、传真及电子邮件 等方式送达给全体监事。应参加会议监事 3 人，实际参加会议监事 3 人。本次 会议采取现场会议的方式召开。本次会议的召集、召开符合《中华人民共和国公 司法》（以下简称《公司法》）及《公司章程》的规定。 二、监事会会议审议情况 （一）审议通过了《2025 年第三季度报告》 表决结果：3 票赞成；0 票弃权；0 票反对。 （二）审议通过了《关于修订<公司章程>的议案》 监事会认为：本由董事会审计委员会代为行使《公司法》规定的监事会职权 符合《公司法》《上市公司章程指引（2025 年修订）》等相关法律法规、规范 性文件的最新 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-021 湖南汉森制药股份有限公司 第六届董事会第九次会议决议的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或者重大遗漏。 一、董事会会议召开情况 湖南汉森制药股份有限公司（以下简称"公司"）第六届董事会第九次会议 于 2025 年 10 月 24 日在公司一楼会议室以现场方式召开，本次会议由公司董事 长刘正清先生召集主持，本次会议通知于 2025 年 10 月 13 日以专人递送、传真 及电子邮件等方式送达给全体董事、监事和高级管理人员。本次会议应参加会议 董事 7 人，实际参加会议董事 7 人。公司监事、高级管理人员列席了本次会议。 本次会议的召集、召开符合《中华人民共和国公司法》及《公司章程》的规定。 二、董事会会议审议情况 （一）审议通过了《2025 年第三季度报告》 《2025 年第三季度报告》（公告编号：2025-023）详见同日的公司指定信 息披露媒体《证券时报》《中国证券报》《上海证券报》《证券日报》和巨潮资 讯网（www.cninfo.com.cn）。 本议案尚需提交公司股东大会审议。 ...

湖南汉森制药股份有限公司 2025 年第三季度报告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗漏。 湖南汉森制药股份有限公司 2025 年第三季度报告 证券代码：002412 证券简称：汉森制药 公告编号：2025-023 重要内容提示： 1.董事会、监事会及董事、监事、高级管理人员保证季度报告的真实、准确、完整，不存在虚假记载、误导性陈 述或重大遗漏，并承担个别和连带的法律责任。 2.公司负责人、主管会计工作负责人及会计机构负责人(会计主管人员)声明：保证季度报告中财务信息的真实、 准确、完整。 3.第三季度财务会计报告是否经过审计 □是 否 一、主要财务数据 （一） 主要会计数据和财务指标 公司是否需追溯调整或重述以前年度会计数据 □是 否 | | 本报告期 | 本报告期比上年同期 | 年初至报告期末 | 年初至报告期末比上 | | --- | --- | --- | --- | --- | | | | 增减 | | 年同期增减 | | 营业收入（元） | 231,943,252.45 | 8.62% | 740,793,882.78 | 6.75% | | ...

Market Overview - The Chinese traditional medicine sector experienced a decline of 0.31% on October 27, with Zhenbaodao leading the drop [1] - The Shanghai Composite Index closed at 3996.94, up 1.18%, while the Shenzhen Component Index closed at 13489.4, up 1.51% [1] Stock Performance - Notable gainers in the traditional medicine sector included: - Weikang Pharmaceutical (300878) with a closing price of 23.90, up 3.46% [1] - ST Xiangxue (300147) at 10.25, up 2.60% [1] - Jiuzi Tang (000989) at 10.02, up 2.14% [1] - Conversely, Zhenbaodao (603567) saw a significant decline of 6.23%, closing at 11.13 [2] - Other notable decliners included: - Taiji Group (600129) down 3.21% [2] - Kunming Pharmaceutical Group (600422) down 2.21% [2] Capital Flow - The traditional medicine sector experienced a net outflow of 344 million yuan from institutional investors, while retail investors saw a net inflow of 181 million yuan [2] - The sector's overall capital flow indicated a mixed sentiment, with speculative funds showing a net inflow of 163 million yuan [2] Individual Stock Capital Flow - Key stocks with significant capital flow included: - Jilin Aodong (000623) with a net inflow of 81.97 million yuan from institutional investors [3] - Yunnan Baiyao (000538) with a net inflow of 62.26 million yuan [3] - Jiuzi Tang (000989) with a net inflow of 26.22 million yuan [3] - Notable outflows were observed in: - Jilin Aodong with a retail net outflow of 72.25 million yuan [3] - Yunnan Baiyao with a retail net outflow of 67.54 million yuan [3]

Market Overview - As of October 27, the Shanghai Composite Index rose by 1.18%, closing at 3996.9445 points, while the Shenzhen Component Index increased by 1.51%, closing at 13489.403 points [1]. Top Gainers in Hunan Stocks - *ST Jingfeng opened at 7.690 and closed at 7.690, with a daily increase of 5.05%, maintaining the same price throughout the day, with a trading volume of 24,128 lots [2]. - Tianqiao Crane opened at 4.210 and closed at 4.340, rising by 4.08%, with a daily high of 4.350 and a low of 4.150, and a trading volume of 1,184,114 lots [2]. - Aoshikang opened at 39.620 and closed at 40.920, up by 3.52%, reaching a high of 41.240 and a low of 39.600, with a trading volume of 62,736 lots [2]. - Yanjinpuzi opened at 69.010 and closed at 70.350, increasing by 3.30%, with a daily high of 71.120 and a low of 68.500, and a trading volume of 36,492 lots [2]. - Hualing Steel opened at 5.740 and closed at 5.910, up by 2.96%, with a high of 5.970 and a low of 5.740, and a trading volume of 1,103,156 lots [2]. Top Losers in Hunan Stocks - Hengli Tui opened at 0.160 and closed at 0.150, experiencing a decline of 11.76%, with a daily high of 0.170 and a low of 0.150, and a trading volume of 611,606 lots [3]. - *ST Gaosi opened at 8.300 and closed at 8.350, down by 2.45%, with a high of 8.450 and a low of 8.130, and a trading volume of 58,408 lots [3]. - Changlan Technology opened at 17.700 and closed at 17.410, decreasing by 1.97%, with a high of 17.780 and a low of 17.200, and a trading volume of 45,737 lots [3]. - Hansen Pharmaceutical opened at 6.620 and closed at 6.510, down by 1.06%, with a high of 6.620 and a low of 6.480, and a trading volume of 94,306 lots [3]. - Hunan Investment opened at 5.730 and closed at 5.630, decreasing by 1.05%, with a high of 5.740 and a low of 5.580, and a trading volume of 171,054 lots [3].

南财智讯10月23日电，汉森制药公告，控股股东海南汉森持有的2450万股股份已解除质押，占其所持股 份比例11.56%，占公司总股本比例4.87%。截至公告日，海南汉森累计质押股份1000万股，占其所持股 份比例4.72%，占公司总股本比例1.99%。 ...

证券代码：002412 证券简称：汉森制药 公告编号：2025-020 湖南汉森制药股份有限公司 关于控股股东部分股份解除质押的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、 误导性陈述或重大遗漏。 湖南汉森制药股份有限公司（以下简称"公司""本公司"）于近日接到控股股 东海南汉森控股（有限合伙）（以下简称"海南汉森"）通知，获悉海南汉森所持有 本公司的部分股份已办理了解除质押手续，具体事项如下： | 股东 名称 | 是否 为控 股股 东 | 本次解除质 押股份数量 （股） | 占其所 持股份 比例(%) | 占公司 总股本 比例(%) | | 起始日 | | 解除日期 | 质权人 | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 海南 汉森 | 是 | 24,500,000 | 11.56 | 4.87 | 2021 21 | 年 6 日 | 月 | 2025年10月 日 22 | 交通银行 股份有限 公司益阳 分行 | | 合计 | - | 24,500,000 | 11.56 | 4.87 ...

Group 1 - The core viewpoint of the news is that Hansoh Pharmaceutical's stock performance and financing activities indicate a stable but cautious market position, with significant financing balances and a slight decline in net profit [1][2]. Group 2 - On October 16, Hansoh Pharmaceutical's stock price remained unchanged at 0.00%, with a trading volume of 33.34 million yuan. The financing buy-in amount was 2.92 million yuan, while the financing repayment was 4.74 million yuan, resulting in a net financing buy-in of -1.83 million yuan [1]. - As of October 16, the total financing and securities lending balance for Hansoh Pharmaceutical was 151 million yuan, with the financing balance accounting for 4.61% of the circulating market value, indicating a high level compared to the past year [1]. - In terms of securities lending, there were no shares repaid or sold on October 16, with the securities lending balance also at 0.00 shares, reflecting a high level compared to the past year [1]. Group 3 - Hansoh Pharmaceutical, established on January 21, 1998, and listed on May 25, 2010, specializes in the research, production, and sales of traditional Chinese medicine, chemical drugs, and medical preparations [2]. - The main revenue sources for Hansoh Pharmaceutical include: Si Mo Tang Oral Liquid (54.81%), Tian Ma Xing Nao Capsules (23.38%), and others, with a diverse product portfolio [2]. - As of August 29, the number of shareholders for Hansoh Pharmaceutical was 23,600, a decrease of 3.43% from the previous period, while the average circulating shares per person increased by 3.55% to 21,113 shares [2]. Group 4 - For the first half of 2025, Hansoh Pharmaceutical achieved an operating income of 509 million yuan, representing a year-on-year growth of 5.91%, while the net profit attributable to the parent company was 68.54 million yuan, a decrease of 31.80% year-on-year [2]. Group 5 - Since its A-share listing, Hansoh Pharmaceutical has distributed a total of 485 million yuan in dividends, with 151 million yuan distributed over the past three years [3].